{"nctId":"NCT01458106","briefTitle":"Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A","startDateStruct":{"date":"2012-11"},"conditions":["Hemophilia A"],"count":71,"armGroups":[{"label":"All participants","type":"EXPERIMENTAL","interventionNames":["Drug: BIIB031 (rFVIIIFc)","Drug: FVIII (PK subgroup only)"]}],"interventions":[{"name":"BIIB031 (rFVIIIFc)","otherNames":["ELOCTATE","efmoroctocog alfa","antihemophilic factor (recombinant), Fc fusion protein","recombinant coagulation factor VIII Fc fusion protein"]},{"name":"FVIII (PK subgroup only)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Severe hemophilia A defined as \\<1 IU/dL (\\<1%) endogenous FVIII\n* Male \\<12 years of age and weight ≥13 kg\n* History of at least 50 documented prior exposure days to FVIII\n* No current, or history of, inhibitor development to FVIII\n\nKey Exclusion Criteria:\n\n* Other coagulation disorders in addition to Hemophilia A\n* History of anaphylaxis associated with any FVIII or IV immunoglobulin administration\n\nNOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"MALE","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Occurrence of FVIII Inhibitor Development","description":"An inhibitor test result ≥0.6 Bethesda units (BU)/mL, confirmed on 2 separate samples drawn 2 to 4 weeks apart, was considered positive. Both tests were to be performed by the central laboratory using the Nijmegen-modified Bethesda Assay. Incidences were summarized for any positive inhibitor for participants with ≥50 EDs to rFVIIIFc. In addition, the incidence for all participants, regardless of their EDs to rFVIIIFc, was also summarized. An exact 95% CI for the proportion of participants with a confirmed inhibitor was calculated using the Clopper-Pearson exact method for a binomial proportion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Bleeding Rate","description":"Annualized bleeding rate = (number of bleeding episodes during the efficacy period / total number of days during the efficacy period)\\*365.25. The efficacy period begins with the first prophylactic dose of rFVIIIFc and ends with the last dose (for prophylaxis or a bleed). Surgery/rehabilitation periods and PK evaluation periods are not included in the efficacy period. A bleeding episode started from the first sign of a bleed and ended no more than 72 hours after the last treatment for the bleed, within which any symptoms of bleeding at the same location or injections less than or equal to 72 hours apart were considered the same bleeding episode. Any injection to treat the bleeding episode taken more than 72 hours after the preceding one was considered the first injection to treat a new bleeding episode at the same location. Any bleeding at a different location was considered a separate bleeding episode, regardless of time from last injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"2.01","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Joint Bleeding Rate (Spontaneous)","description":"Annualized bleeding rate for spontaneous joint bleed=(number of bleeding episodes meeting those criteria during the efficacy period/total number of days during the efficacy period)\\*365.25. The efficacy period begins with the first prophylactic dose of rFVIIIFc and ends with the last dose (for prophylaxis or a bleed). Surgery/rehabilitation periods and PK evaluation periods are not included in the efficacy period. A bleeding episode started from the first sign of a bleed and ended no more than 72 hours after the last treatment for the bleed, within which any symptoms of bleeding at the same location or injections less than or equal to 72 hours apart were considered the same bleeding episode. Any injection to treat the bleeding episode taken more than 72 hours after the preceding one was considered the first injection to treat a new bleeding episode at the same location. Any bleeding at a different location was considered a separate bleeding episode, regardless of time from last inject","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Participant Assessment of Response to Injections to Treat a Bleeding Episode","description":"Participant's assessment (provided by the caregiver) of the response to the first rFVIIIFc injection for each bleeding episode. Percentages were based on the number of first injections for which a response was provided, using the following 4-point scale: excellent=abrupt pain relief and/or improvement in signs of bleeding within approximately 8 hours after the initial injection; good=definite pain relief and/or improvement in signs of bleeding within approximately 8 hours after a single injection, but possibly requiring more than one injection after 24 to 48 hours for complete resolution; moderate=probable or slight beneficial effect within approximately 8 hours after the initial injection and requiring more than one injection; no response=no improvement, or condition worsened, within approximately 8 hours after the initial injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.4","spread":null},{"groupId":"OG001","value":"93.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.7","spread":null},{"groupId":"OG001","value":"47.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","spread":null},{"groupId":"OG001","value":"45.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician's Global Assessment of the Participant's Response to His rFVIIIFc Regimen","description":"Investigators assessed each participant's response to his rFVIIIFc regimen using a 4-point scale: excellent=bleeding episodes responded to ≤ the usual number of injections or ≤ the usual dose of rFVIIIFc or the rate of breakthrough bleeding during prophylaxis was ≤ that usually observed; effective=most bleeding episodes responded to the same number of injections and dose, but some required more injections or higher doses, or there was a minor increase in the rate of breakthrough bleeding; partially effective=bleeding episodes most often required more injections and/or higher doses than expected, or adequate breakthrough bleeding prevention during prophylaxis required more frequent injections and/or higher doses; ineffective=routine failure to control hemostasis, or hemostatic control required additional agents. Percentages are based on the total number of responses; multiple responses per participant are counted.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.5","spread":null},{"groupId":"OG001","value":"89.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized rFVIIIFc Consumption Per Participant","description":"Consumption is calculated for the efficacy period. The efficacy period begins with the first prophylactic dose of rFVIIIFc and ends with the last dose (for prophylaxis or a bleed). Surgery/rehabilitation periods and PK evaluation periods are not included in the efficacy period. Annualized consumption = (total IU/kg of study treatment received during the efficacy period / total number of days during the efficacy period)\\*365.25. Consumption was calculated overall for all participants and for the last 3 months (91 days) on study, counted backwards from the end of the efficacy period, for participants with at least 24 weeks on study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5331.8","spread":"1106.68"},{"groupId":"OG001","value":"4973.5","spread":"976.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5562.1","spread":"1474.42"},{"groupId":"OG001","value":"5092.6","spread":"1013.01"}]}]}]},{"type":"SECONDARY","title":"Number of Days From Last Treatment Injection to a Spontaneous Bleeding Episode","description":"The number of days from the last prophylaxis injection to the onset of a new spontaneous bleeding episode, analyzed across all evaluable bleeding episodes per participant and per episode, based on the efficacy period. Evaluable bleeding episodes are those for which both a date and time are available for both the onset of the bleeding episode and the previous prophylactic injection. The efficacy period begins with the first prophylactic dose of rFVIIIFc and ends with the last dose (for prophylaxis or a bleed). Surgery/rehabilitation periods and PK evaluation periods are not included in the efficacy period. For 'Per participant' values, the number of days from the last prophylactic injection to a spontaneous bleeding episode is averaged across all evaluable spontaneous bleeding episodes per participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.17","spread":null},{"groupId":"OG001","value":"2.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.16","spread":null},{"groupId":"OG001","value":"2.77","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Injections Required for Resolution of a Bleeding Episode","description":"The number of injections required to resolve a bleeding episode per participant and per episode, based on the efficacy period. The efficacy period begins with the first prophylactic dose of rFVIIIFc and ends with the last dose (for prophylaxis or a bleed). Surgery/rehabilitation periods and PK evaluation periods are not included in the efficacy period. All injections given from the initial sign of a bleed, until the last date/time within the bleed window are counted. The resolution of a bleed is defined as no sign of bleeding following injection for the bleed. For 'Per participant' values, the number of injections required to resolve each bleed is averaged across all bleeding episodes per participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Dose Required for Resolution of a Bleeding Episode","description":"The total dose required to resolve a bleeding episode per participant and per episode, based on the efficacy period. The efficacy period begins with the first prophylactic dose of rFVIIIFc and ends with the last dose (for prophylaxis or a bleed). Surgery/rehabilitation periods and PK evaluation periods are not included in the efficacy period. For 'Per bleeding episode' values, for each bleeding episode, the total dose is the sum of the doses (IU/kg) administered across all injections given to treat that bleeding episode. For 'Per participant' values, the total dose (IU/kg) used to resolve each bleed is averaged across all bleeding episodes per participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.56","spread":null},{"groupId":"OG001","value":"51.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.40","spread":null},{"groupId":"OG001","value":"53.49","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Plasma Activity (Cmax; One-stage Activated Partial Thromboplastin Time [aPTT] Clotting Assay)","description":"Maximum plasma activity during a dosing interval for participants in the PK subgroup. The values for Cmax were adjusted to the nominal dose of 50 IU/kg. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.03","spread":null},{"groupId":"OG001","value":"114.94","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Plasma Activity (Cmax; Two-stage Chromogenic Assay)","description":"Maximum plasma activity during a dosing interval for participants in the PK subgroup. The values for Cmax were adjusted to the nominal dose of 50 IU/kg. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.11","spread":null},{"groupId":"OG001","value":"103.80","spread":null}]}]}]},{"type":"SECONDARY","title":"Elimination Half Life (t1/2; One-stage aPTT Clotting Assay)","description":"Time required for the activity of the drug to reach half of its original value for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.277","spread":null},{"groupId":"OG001","value":"13.451","spread":null}]}]}]},{"type":"SECONDARY","title":"Elimination Half Life (t1/2; Two-stage Chromogenic Assay)","description":"Time required for the activity of the drug to reach half of its original value for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.268","spread":null},{"groupId":"OG001","value":"15.861","spread":null}]}]}]},{"type":"SECONDARY","title":"Clearance (CL; One-stage aPTT Clotting Assay)","description":"Rate at which the body removes the drug, measured as the volume of the plasma cleared of drug per unit time per unit weight for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4561","spread":null},{"groupId":"OG001","value":"2.6067","spread":null}]}]}]},{"type":"SECONDARY","title":"Clearance (CL; Two-stage Chromogenic Assay)","description":"Rate at which the body removes the drug, measured as the volume of the plasma cleared of drug per unit time per unit weight for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8600","spread":null},{"groupId":"OG001","value":"3.0486","spread":null}]}]}]},{"type":"SECONDARY","title":"Volume at Steady State (Vss; One-stage aPTT Clotting Assay)","description":"Volume of distribution at steady state for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.94","spread":null},{"groupId":"OG001","value":"49.51","spread":null}]}]}]},{"type":"SECONDARY","title":"Volume at Steady State (Vss; Two-stage Chromogenic Assay)","description":"Volume of distribution at steady state for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.48","spread":null},{"groupId":"OG001","value":"63.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Dose Normalized Area Under the Curve (DNAUC; One-stage aPTT Clotting Assay)","description":"Dose normalized area under the FVIII activity-time curve for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.93","spread":null},{"groupId":"OG001","value":"38.37","spread":null}]}]}]},{"type":"SECONDARY","title":"Dose Normalized Area Under the Curve (DNAUC; Two-stage Chromogenic Assay)","description":"Dose normalized area under the FVIII activity-time curve for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.90","spread":null},{"groupId":"OG001","value":"32.80","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Residence Time (MRT; One-stage aPTT Clotting Assay)","description":"The average time that a drug molecule is present in the systemic circulation for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.762","spread":null},{"groupId":"OG001","value":"18.999","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Residence Time (MRT; Two-stage Chromogenic Assay)","description":"The average time that a drug molecule is present in the systemic circulation for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.220","spread":null},{"groupId":"OG001","value":"20.708","spread":null}]}]}]},{"type":"SECONDARY","title":"Incremental Recovery (IR; One-stage aPTT Clotting Assay)","description":"The rise in FVIII activity in IU/dL per unit dose administered in IU/kg for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.901","spread":null},{"groupId":"OG001","value":"2.299","spread":null}]}]}]},{"type":"SECONDARY","title":"Incremental Recovery (IR; Two-stage Chromogenic Assay)","description":"The rise in FVIII activity in IU/dL per unit dose administered in IU/kg for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.882","spread":null},{"groupId":"OG001","value":"2.076","spread":null}]}]}]},{"type":"SECONDARY","title":"Time at Maximum Activity (Tmax; One-stage aPTT Clotting Assay)","description":"Time at which maximum activity (Cmax) is observed for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6987","spread":null},{"groupId":"OG001","value":"0.7257","spread":null}]}]}]},{"type":"SECONDARY","title":"Time at Maximum Activity (Tmax; Two-stage Chromogenic Assay)","description":"Time at which maximum activity (Cmax) is observed for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7313","spread":null},{"groupId":"OG001","value":"0.6334","spread":null}]}]}]},{"type":"SECONDARY","title":"Lambda Z (One-stage aPTT Clotting Assay)","description":"First order rate constant associated with the terminal portion of the curve (lambda z) for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05644","spread":null},{"groupId":"OG001","value":"0.05158","spread":null}]}]}]},{"type":"SECONDARY","title":"Lambda Z (Two-stage Chromogenic Assay)","description":"First order rate constant associated with the terminal portion of the curve (lambda z) for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04848","spread":null},{"groupId":"OG001","value":"0.04367","spread":null}]}]}]},{"type":"SECONDARY","title":"Volume at Terminal Phase (Vz; One-stage aPTT Clotting Assay)","description":"Volume of distribution estimated from the terminal phase for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.22","spread":null},{"groupId":"OG001","value":"50.58","spread":null}]}]}]},{"type":"SECONDARY","title":"Volume at Terminal Phase (Vz; Two-stage Chromogenic Assay)","description":"Volume of distribution estimated from the terminal phase for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.48","spread":null},{"groupId":"OG001","value":"69.75","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve to the Last Measurable Timepoint (AUClast; One-stage aPTT Clotting Assay)","description":"Dose-normalized area under the FVIII activity-time curve to the last measurable timepoint for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1410.4","spread":null},{"groupId":"OG001","value":"1823.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve to the Last Measurable Timepoint (AUClast; Two-stage Chromogenic Assay)","description":"Dose-normalized area under the FVIII activity-time curve to the last measurable timepoint for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1250.1","spread":null},{"groupId":"OG001","value":"1540.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve to Infinity (AUCinf; One-stage aPTT Clotting Assay)","description":"Dose normalized area under the FVIII activity-time curve to infinity for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1446.5","spread":null},{"groupId":"OG001","value":"1918.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve to Infinity (AUCinf; Two-stage Chromogenic Assay)","description":"Dose normalized area under the FVIII activity-time curve to infinity for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1294.7","spread":null},{"groupId":"OG001","value":"1640.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of AUCinf Extrapolated From the Last Data Point to Infinity (%AUCext; One-stage aPTT Clotting Assay)","description":"Percentage of AUCinf extrapolated from the last data point to infinity for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8421","spread":null},{"groupId":"OG001","value":"2.7777","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of AUCinf Extrapolated From the Last Data Point to Infinity (%AUCext; Two-stage Chromogenic Assay)","description":"Percentage of AUCinf extrapolated from the last data point to infinity for participants in the PK subgroup. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7530","spread":null},{"groupId":"OG001","value":"3.9476","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":35},"commonTop":["Cough","Upper Respiratory Tract Infection","Nasopharyngitis","Abdominal Pain Upper","Vomiting"]}}}